Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies
- PMID: 38893199
- PMCID: PMC11171228
- DOI: 10.3390/cancers16112080
Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies
Abstract
Prostate cancer lung metastasis represents a clinical conundrum due to its implications for advanced disease progression and the complexities it introduces in treatment planning. As the disease progresses to distant sites such as the lung, the clinical management becomes increasingly intricate, requiring tailored therapeutic strategies to address the unique characteristics of metastatic lesions. This review seeks to synthesize the current state of knowledge surrounding prostate cancer metastasis to the lung, shedding light on the diverse array of clinical presentations encountered, ranging from subtle radiological findings to overt symptomatic manifestations. By examining the diagnostic modalities utilized in identifying this metastasis, including advanced imaging techniques and histopathological analyses, this review aims to provide insights into the diagnostic landscape and the challenges associated with accurately characterizing lung metastatic lesions in prostate cancer patients. Moreover, this review delves into the nuances of therapeutic interventions employed in managing prostate cancer lung metastasis, encompassing systemic treatments such as hormonal therapies and chemotherapy, as well as metastasis-directed therapies including surgery and radiotherapy.
Keywords: lung metastasis; metastasis-directed therapy; prostate cancer; systemic therapy.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
Progress in Oligometastatic Prostate Cancer: Emerging Imaging Innovations and Therapeutic Approaches.Cancers (Basel). 2024 Jan 24;16(3):507. doi: 10.3390/cancers16030507. Cancers (Basel). 2024. PMID: 38339259 Free PMC article. Review.
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
The Arterial Axis Lesions in Proximal Humeral Fractures-Case Report and Literature Review.J Pers Med. 2023 Dec 14;13(12):1712. doi: 10.3390/jpm13121712. J Pers Med. 2023. PMID: 38138939 Free PMC article.
-
Game-changing insights on vertebral skeletal stem cells in bone metastasis and therapeutic horizons.Oncol Res. 2023 Nov 15;32(1):95-98. doi: 10.32604/or.2023.046174. eCollection 2023. Oncol Res. 2023. PMID: 38188672 Free PMC article.
-
Oligometastatic Prostate Cancer-The Middle Child Syndrome.J Clin Med. 2023 Nov 21;12(23):7198. doi: 10.3390/jcm12237198. J Clin Med. 2023. PMID: 38068251 Free PMC article. Review.
Cited by
-
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer.Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):305-313. doi: 10.1007/s00259-024-06856-x. Epub 2024 Jul 31. Eur J Nucl Med Mol Imaging. 2024. PMID: 39083067 Free PMC article.
References
-
- Goodman O.B., Flaig T.W., Molina A., Mulders P.F.A., Fizazi K., Suttmann H., Li J., Kheoh T., de Bono J.S., Scher H.I. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014;17:34–39. doi: 10.1038/pcan.2013.41. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials